Protective effects of atractylenolide III on oxygen‐glucose‐deprivation/reperfusion‐induced injury in HT22 cells
Roujia Guo,Siqi Quan,Yuan Liu,Jiahui Wang,Ziyang Huang,Xiuhui Guo,Ming Bai,Erping Xu,Xiangli Yan,Yucheng Li
DOI: https://doi.org/10.1177/09603271241288508
2024-09-28
Human & Experimental Toxicology
Abstract:Human &Experimental Toxicology, Volume 43, Issue , January-December 2024. BackgroundAtractylenolide III (ATL III) is a natural bioactive compound, that possesses anti-inflammatory, antioxidant, and neuroprotective properties. However, whether ATL III can protect against neuronal injury induced by cerebral ischemia/reperfusion (I/R) have not yet been studied. This study aimed to investigate the protective effects of ATL III on neuronal injury using an oxygen-glucose deprivation/reperfusion (OGD/R) model in HT22 cells.MethodsEstablishment of OGD/R model to induce HT22 cell injury in vitro. Cell viability, live-dead cell staining, oxidative stress levels, and pro-inflammatory cytokine levels were detected using kits. Cell apoptosis was observed by flow cytometry, and the expression of Bax, Bcl-2, and Caspase-3 proteins was detected by western blot.ResultsATL III significantly alleviates OGD/R-induced cell injury, as evidenced by the increased cell viability and reduced apoptosis rate. ATL III increased the levels of superoxide dismutase (SOD) and glutathione (GSH), while reducing malondialdehyde (MDA), reactive oxygen species (ROS), and the levels of TNF-α, IL-1β, and IL-6. The protein expression of Bax and Caspase-3 was downregulated, while Bcl-2 expression was upregulated by ATL III.ConclusionATL III as a potential therapeutic agent for reducing neuronal injury by mitigating oxidative stress, apoptosis, and inflammation.
toxicology